Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18

Molecular Biotechnology

Volumn 54, Issue 2, 2013, Pages 361-370

  Liu, Hai Bo ^a   Chaturvedi, Pankaj Kumar ^a   Battogtokh, Gantumur ^a   Bang, Hyo Joo ^a   Kim, In Wook ^a   Kim, Yong Wan ^a   Park, Kye Shin ^b   Ahn, Woong Shick ^a  

^a The Catholic University of Korea   (South Korea)

^b Diatech Korea   (South Korea)

Author keywords

Antibody; Human papillomavirus (HPV); Immunoassay; Vaccine; Virus like particle (VLP)

Indexed keywords

ANTIBODY CONCENTRATION; COMPETITIVE IMMUNOASSAY; DETECTION AND QUANTIFICATIONS; GLUTATHIONE-S-TRANSFERASE; HUMAN PAPILLOMAVIRUS; IMMUNOASSAY; NEUTRALIZING ANTIBODIES; VIRUS-LIKE PARTICLES;

ANTIBODIES; IMMUNOLOGY; MONOCLONAL ANTIBODIES; ONCOGENIC VIRUSES; OPTIMIZATION; PROTEINS; VACCINES;

CHEMICAL DETECTION;

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS PROTEIN;

ACCURACY; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DILUTION; ESCHERICHIA COLI; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOASSAY; INCUBATION TIME; NONHUMAN; SENSITIVITY ANALYSIS; VIRUS LIKE AGENT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; CAPSID PROTEINS; CROSS REACTIONS; ESCHERICHIA COLI; GLUTATHIONE TRANSFERASE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOASSAY; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROTEIN RENATURATION; RECOMBINANT PROTEINS;

BACTERIA (MICROORGANISMS); HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 84882823720     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-012-9571-2     Document Type: Article

References (27)

1. Munoz, N., Bosch, F. X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K. V., et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. The New England Journal of Medicine, 348, 518-527.
2. Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J., & Burk, R. D. (1998). Natural history of cervicovaginal papillomavirus infection in young women. The New England Journal of Medicine, 338, 423-428.
3. Roberts, J. N., Buck, C. B., & Thompson, C. D. (2007). Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nature Medicine, 13, 857-861.
4. Lowy, D. R., & Howley, P. M. (2001). Papillomaviruses and their replication. Philadelphia, PA: Lippincott Williams & Wilkins.
5. Breitburd, F., Kirnbauer, R., Hubbert, N. L., Nonnenmacher, B., Trin-Dinh-Desmarquet, C., Orth, G., et al. (1995). Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. Journal of Virology, 69, 3959-3963.
6. Kirnbauer, R., Chandrachud, L. M., O'Neil, B. W., Wagner, E. R., Grindlay, G. J., Armstrong, A., et al. (1996). Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology, 219, 37-44.
7. Suzich, J. A., Ghim, S. J., Palmer-Hill, F. J., White, W. I., Tamura, J. K., Bell, J. A., et al. (1995). Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proceedings of the National Academy of Sciences USA, 92, 11553-11557.
8. Ault, K. A., Giuliano, A. R., Edwards, R. P., Tamms, G., Kim, L. L., Smith, J. F., et al. (2004). A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine, 22, 3004-3007.
9. Brown, D. R., Fife, K. H., Wheeler, C. M., Koutsky, L. A., Lupinacci, L. M., Railkar, R., et al. (2004). Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine, 22, 2936-2942.
10. Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., et al. (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. The Lancet, 364, 1757-1765.
11. Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., et al. (2002). A controlled trial of a human papillomavirus type 16 vaccine. The New England Journal of Medicine, 347, 1645-1651.
12. Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., et al. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. The Lancet Oncology, 6, 271-278.
13. Yeager, M. D., Aste-Amezaga, M., Brown, D. R., et al. (2000). Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology, 278, 570-577.
14. Palker, T. J., Monteiro, J. M., Martin, M. M., et al. (2001). Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine, 19, 3733-3743.
15. Opalka, D., Lachman, C. E., MacMullen, S. A., et al. (2003). Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clinical and Diagnostic Laboratory Immunology, 10, 108-115.
16. Dias, D., Doren, J. V., Schlottmann, S., et al. (2005). Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clinical and Diagnostic Laboratory Immunology, 12, 959-969.
17. Chen, X. S., Garcea, R. L., Goldberg, I., Casini, G., & Harrison, S. C. (2000). Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Molecular Cell, 5, 557-567.
18. Yuan, H., Estes, P. A., Chen, Y., Newsome, J., Olcese, V. A., Garcea, R. L., et al. (2001). Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. Journal of Virology, 75, 7848-7853.
19. Cho, E. J., Do, J. H., Kim, Y. S., Bae, S., & Ahn, W. S. (2011). Evaluation of a liquid bead array system for high-risk human papillomavirus detection and genotyping in comparison with Hybrid Capture II, DNA chip and sequencing methods. Journal of Medical Microbiology, 60, 162-171.
20. Oh, Y., Bae, S. M., Kim, Y. W., Choi, H. S., Nam, G. H., Han, S. J., et al. (2007). Polymerase chain reaction-based fluorescent Luminex assay to detect the presence of human papillomavirus types. Cancer Science, 98, 549-554.
21. Sehr, P., Zumbach, K., & Pawlita, M. (2001). A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. Journal of Immunological Methods, 253, 153-162.
22. Bradford, M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248-254.
23. Liao, S., Wang, S., Xu, L., Deng, D., Xu, Q., Wang, W., et al. (2008). Production and verification of human papillomavirus type 18 vaccine in vitro. Oncology Report, 20, 211-217.
24. Woo, M. K., An, J. M., Park, J. D., Kim, S. N., & Kim, H. J. (2008). Expression and purification of human papillomavirus 18 L1 virus-like particle from Saccharomyces cerevisiae. Archives of Pharmacal Research, 31, 205-209.
25. Senger, T., Schädlich, L., Textor, S., Klein, C., Michael, K. M., Buck, C. B., et al. (2010). Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. Vaccine, 28, 1583-1593.
26. Seo, P. S., Heo, S. Y., Han, E. J., Seo, J. W., Ghim, S. J., & Kim, C. H. (2009). Bacterial expression and purification of human papillomavirus type 18 L1. Biotechnology and Bioprocess Engineering, 14, 168-174.
27. Chen, X. S., Casini, G., Harrison, S. C., & Garcea, R. L. (2001). Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. Journal of Molecular Biology, 307, 173-182.